EverPoint Asset Management’s Integra LifeSciences IART Stock Holding History

EverPoint Asset Management’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-300,000	Closed	-$12M	–	451
2016 Q2	$12M	Sell	300,000 -90,000	-23%	-$3.24M	0.24%	124
2016 Q1	$13.1M	Buy	390,000 +20,000	+5%	+$623K	0.26%	102
2015 Q4	$12.5M	Sell	370,000 -80,000	-18%	-$2.5M	0.26%	121
2015 Q3	$13.4M	Buy	+450,000	New	+$14.1M	0.35%	79

Other funds holding IART

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EverPoint Asset Management's IART Position: Q3 2016 in Review

EverPoint Asset Management sold out of Integra LifeSciences (IART) in Q3 2016, closing a stake of 300,000 shares — an estimated $12M sold.

EverPoint Asset Management first reported a position in IART in Q3 2015 and held it in 4 quarters. The position peaked at $13.4M in Q3 2015. 235 funds tracked by Wall St. Rank hold IART as of Q3 2016.

EverPoint Asset Management reported no remaining Integra LifeSciences position as of Q3 2016 after selling out during the quarter.
EverPoint Asset Management sold 300,000 Integra LifeSciences shares in Q3 2016, an estimated $12M.
EverPoint Asset Management first reported a position in Integra LifeSciences in Q3 2015 and held it in 4 quarters.
EverPoint Asset Management's Integra LifeSciences position peaked at $13.4M in Q3 2015.
235 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2016.

Based on EverPoint Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.